en · de · es · fr · pt
creatine-notes.peptides4800.com › Faq › Identity And Reported Background — Hands-On Walkthrough

Identity And Reported Background — Hands-On Walkthrough

By Editorial Desk · published 2026-03-21 · last reviewed 2026-04-14 · Faq

TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-04-14 and is reviewed periodically as new material appears.

Identity and Reported Background

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Research Framing and Evidence Base

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Tb-500 at a glance

PropertyValueNotes
Reported sequenceAc-LKKTETQDescribed in most listings as the actin-binding region of thymosin beta-4
Reported molecular weightApproximately 889 DaValue shifts with the stated sequence; compare against the certificate of analysis
Parent protein length43 amino acidsThymosin beta-4; the fragment covers only a small part of it
Common synonymsTB4 fragment; thymosin beta-4 fragmentTrade-style names rather than formal nomenclature
Formal monographsNot establishedLabeling conventions differ by supplier and region

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

Related pages on this site

Identification and Molecular Background

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Background from the literature

=== Geroprotective activity === Didymin is the principal flavonoid constituent of Monarda didyma L. (scarlet beebalm) extract, occurring at concentrations approximately 80-fold higher than the only other detectable flavonoid, isosakuranetin. In a randomized clinical trial, supplementation with 100 mg/day of Monarda didyma L. extract over 12 weeks was associated with reduced telomere attrition and improvements in markers of biological aging and quality of life, with the effects attributed primarily to didymin.

=== Radiological cleanup === A radiological survey of Enewetak was conducted from 1972 to 1973. In 1977, the United States military began decontamination of Enewetak and other islands. During the three-year, US$100 million cleanup process, the military mixed more than 80,000 cubic meters (100,000 cu yd) of contaminated soil and debris from the islands with Portland cement and buried it in an atomic blast crater on the northern end of the atoll's Runit Island. The material was placed in the 9.1-meter (30 ft) deep, 110-meter (360 ft) wide crater created by the May 5, 1958, "Cactus" nuclear weapons test. A dome composed of 358 concrete panels, each 46 centimeters (18 in) thick, was constructed over the material. The final cost of the cleanup project was US$239 million. The United States government declared the southern and western islands in the atoll safe for habitation in 1980, and residents of Enewetak returned that same year. The military members who participated in that cleanup mission are suffering from many health issues, but the U.S. Government refused to provide health coverage until 2022 with the passage of the Honoring our PACT Act. The 2000 environmental restoration award included funds for additional cleanup of radioactivity on Enewetak. Rather than scrape the topsoil off, replace it with clean topsoil, and create another radioactive waste repository dome at some site on the atoll (a project estimated to cost US$947 million), most areas still contaminated on Enewetak were treated with potassium.

Aminoacyl tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Threonyl-tRNA synthetase belongs to the class-II aminoacyl-tRNA synthetase family.

Binding of a ligand to a binding site on protein often triggers a change in conformation in the protein and results in altered cellular function. Hence binding site on protein are critical parts of signal transduction pathways. Types of ligands include neurotransmitters, toxins, neuropeptides, and steroid hormones. Binding sites incur functional changes in a number of contexts, including enzyme catalysis, molecular pathway signaling, homeostatic regulation, and physiological function. Electric charge, steric shape and geometry of the site selectively allow for highly specific ligands to bind, activating a particular cascade of cellular interactions the protein is responsible for.

The investigation by Science and the NIH was triggered by whistleblowers who delivered a 113 page dossier to Science. The dossier presented evidence that patients treated with 3K3A-APC died at a higher rate in the first week following treatment than those on the placebo (6 out of 66 versue 1 out 44). Also, patients on the drug suffered more disability. The dossier also claimed that data had been doctored in dozens of papers from Zlokovic's lab. Wade Smith, a University of California, San Francisco neurologist and StrokeNet principal investigator said that “I think pausing the trial until any impact of potential impropriety in preclinical drug testing is resolved to ensure the compound is safe for humans is the correct pathway to follow. This drug may work in humans so discarding it would be a shame,” he adds. “Alternatively, moving forward with a compound that may be unsafe is worse.”

Sources: en.wikipedia.org

Reference notes

=== Xenon-135 oscillations === The interdependence of 135Xe buildup and the neutron flux can lead to periodic power fluctuations. In large reactors, with little neutron flux coupling between their regions, flux nonuniformities can lead to formation of xenon oscillations, periodic local variations of reactor power moving through the core with a period of about 15 hours. A local variation of neutron flux causes increased burnup of 135Xe and production of 135I, depletion of 135Xe increases the reactivity in the core region. The local power density can change by a factor of three or more, while the average power of the reactor stays more or less unchanged. Strong negative temperature coefficient of reactivity causes damping of these oscillations, and is a desired reactor design feature.

=== Social construct === Beyond the genetic, epigenetic, and biological factors that can contribute to an autism diagnosis are theories related to the "autistic identity". It has been theorized that perceptions towards the characteristics of autistic individuals have been heavily influenced by neurotypical ideologies and social norms. The social construct theory says that the boundary between normal and abnormal is subjective and arbitrary, so autism does not exist as an objective entity, but only as a social construct. It further argues that autistic individuals themselves have a way of being that is partly socially constructed. Mild and moderate variations of autism are particular targets of the theory that social factors determine what it means to be autistic. The theory hypothesizes that individuals with these diagnoses inhabit the identities that have been ascribed to them, and promote their sense of well-being by resisting or appropriating autistic ascriptions. Lynn Waterhouse suggests that autism has been reified, in that social processes have endowed it with more reality than is justified by the scientific evidence. Although social construction of the autistic identity can have a positive impact on the well-being and treatment of autistic individuals, that is not always the case when the individuals in question belong to historically marginalized populations.

Iguarán scored twice in a 2–0 win over Ecuador in Barranquilla on 20 August, and after a 2–1 defeat in Asunción — conceded to a stoppage-time penalty from the debutant José Luis Chilavert — and a goalless draw in Guayaquil, Colombia beat Paraguay 2–1 in Barranquilla through Iguarán and Rubén Hernández. Ecuador's 3–1 win over Paraguay on 24 September confirmed Colombia as group winners and sent them to an intercontinental play-off. Against Israel, winners of the Oceania group, Usuriaga scored the only goal of the first leg in Barranquilla on 15 October before 65,000 spectators. A goalless draw at the Ramat Gan Stadium in Tel Aviv on 30 October 1989 completed a 1–0 aggregate victory and returned Colombia to the World Cup after an absence of 28 years.

==== Contamination of water supply ==== In 2005, the water supply to the city of Harbin in China with a population of almost nine million people, was cut off because of a major benzene exposure. Benzene leaked into the Songhua River, which supplies drinking water to the city, after an explosion at a China National Petroleum Corporation (CNPC) factory in the city of Jilin on 13 November 2005. When plastic water pipes are subject to high heat, the water may be contaminated with benzene.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.

Why do product descriptions differ between suppliers?

Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.

What mechanism is most often proposed?

The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.

Network